除了加大在华研发投入,辉瑞正通过与本土药企合作,进一步拓宽在华业务边界。在过去,跨国药企的全球临床研究布局中,中国市场的权重明显偏低。在多数企业的内部计划里,在华研究中心的参与度不足,中国患者的入组规模也处于低位。这直接导致,即便中国参与了相关全球研究,但其积累的研究数据和患者样本量,仍难以满足对应新药在中国的适应症审批要求。跨国药企若想推动创新药在华落地商业化,往往需要在中国单独启动一项本土化...
Source Link除了加大在华研发投入,辉瑞正通过与本土药企合作,进一步拓宽在华业务边界。在过去,跨国药企的全球临床研究布局中,中国市场的权重明显偏低。在多数企业的内部计划里,在华研究中心的参与度不足,中国患者的入组规模也处于低位。这直接导致,即便中国参与了相关全球研究,但其积累的研究数据和患者样本量,仍难以满足对应新药在中国的适应症审批要求。跨国药企若想推动创新药在华落地商业化,往往需要在中国单独启动一项本土化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.